AXSMAxsome Therapeutics, Inc.
Price
+45%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, growing in the filings, the market undecided.
We are a fully integrated biopharmaceutical company focused on developing innovative medicines for people impacted by central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and developing differentiated products with a focus on novel mechanisms of action, that have the potential to transform patient outcomes.
In the company’s own words · 10-K filed Feb 23, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Axsome Therapeutics, Inc. (AXSM) reported revenue of $218M in Q2 2026 (quarter ended Jun 30, 2026), up 46% from the same quarter a year earlier. That came with a gross margin of 94% and net loss of $51M. For the full year FY2025, revenue was $638M (+66% year on year) and net income −$183M. Its largest product in Q2 2026 was Royalty And Milestone at $2.0M, 66% of the disclosed total, well ahead of Milestone at 18%. The next results filing is expected around Nov 2, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 10, 2026On August 10, 2026, the Company updated its corporate presentation and posted such corporate presentation to the Company’s website.Earnings release · Form 8-K
- Jul 15, 2026On July 15, 2026, Axsome Therapeutics, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application for AXS-12 (reboxetine) for the treatment of cataplexy in narcolepsy.Other event · Form 8-K
- Jun 3, 2026Axsome Therapeutics Announces Settlement Resolving All SUNOSI ® (solriamfetol) Patent Litigation.Other event · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $3.1MThe company’s own SEC segment disclosure.
- Royalty And Milestone$2.0M66%
- Milestone$546.0K18%
- Royalty$500.0K16%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.